Okamoto, Yuko

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Department of Pharmacy Social Pharmacy ( Shiba-Kyoritsu )

Position

Research Associate/Assistant Professor/Instructor
Page Top ▲

Career 【 Display / hide 】

  • 2018.04
    -
    2018.09

    株式会社 SKY CREATE 海浜総合薬局　薬剤師

  • 2018.10
    -
    2019.11

    シドニー大学薬学部 訪問研究員

  • 2019.12
    -
    2021.12

    アドバンス株式会社　さくら調剤薬局　薬剤師

  • 2021.12
    -
    2024.04

    株式会社 SKY CREATE 海浜総合薬局　管理薬剤師

  • 2024.05
    -
    2025.12

    慶應義塾大学薬学部　実務実習事前学習（実習）補助

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2008.04
    -
    2014.03

    Sojo University

    University, Graduated

  • 2014.04
    -
    2018.03

    Sojo University

    Graduate School, Completed, Doctoral course

Page Top ▲
 

Papers 【 Display / hide 】

  • Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

    Mizukami Y., Takahashi M., Suzuki K., Duan S., Ikegami S., Muraishi T., Satake N., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

    Journal of Infection and Chemotherapy 32 ( 1 ) 102889 2026.01

    Research paper (scientific journal), Accepted,  ISSN  1341321X

    　View Summary

    Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Effect of PEGylation on the physicochemical and pharmacokinetic characteristics of bovine serum albumin-encapsulated liposome

    Yuko Okamoto, Kazuaki Taguchi, Keishi Yamasaki, Mina Sakuragi, Shun’ichi Kuroda, Masaki Otagiri

    Asian Journal of Pharmaceutical Sciences  2025.11

    Research paper (international conference proceedings), Lead author

  • Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

    Kawasaki A., Shintani R., Takao R., Nakazawa Y., Mihara T., Ikegami S., Shimada S., Matsumoto Y., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

    Medical Mycology 63 ( 10 )  2025.10

    Research paper (scientific journal), Accepted,  ISSN  13693786

    　View Summary

    Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Analysis of Drug-Induced Xerostomia using the Japanese Adverse Drug Event Report Database.

    Shingo Kondo, Mari Maese, Nozomi Ito, Yuko Okamoto, Hiroki Iwata, Noriko Kobayashi, Katsunori Yamaura

    BPB Reports  2025.10

    Research paper (scientific journal), Accepted

  • 医療用一般用共用医薬品 (仮称) の創設提言に対する薬剤師の認知および見解に関する実態把握調査.

    (医療薬学)  51 ( 4 ) 196 - 202 2025.04

    Research paper (scientific journal), Lead author, Accepted

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications

    Kazuaki Taguchi, Yuko Okamoto, Kazuaki Matsumoto, Masaki Otagiri, Victor Tuan Giam Chuang

    Pharmaceuticals  2021.03

    Article, review, commentary, editorial, etc. (scientific journal)

  • Topical application of bacteriophages for treatment of wound infections

    Rachel Yoon Kyung Chang, Sandra Morales, Yuko Okamoto, Hak-Kim Chan

    Translational Research  2020.03

    Article, review, commentary, editorial, etc. (scientific journal)

Page Top ▲

Presentations 【 Display / hide 】

  • CREによる肺炎マウスモデルを用いたNAC/CFPM併用療法時の目標T＞MICi値

    水上 雄貴, 岡本 侑子, 五十嵐 裕貴, 榎木 裕紀, 田口 和明, 池上 眞太郎, 鈴木 健太, 高橋 実秀, 松元 一明

    [Domestic presentation]  第35回日本医療薬学会年会, 

    2025.11
    , 

    Oral presentation (general)

  • ポサコナゾールの血清タンパク質への結合特性の解析

    岡本 侑子, 田口 和明,五十嵐 裕貴, 榎木 裕紀, 松元 一明

    [Domestic presentation]  第35回日本医療薬学会年会, 

    2025.11
    , 

    Poster presentation

  • 肺炎球菌ワクチン単剤接種または併用接種時の有効性および安全性比較: システマティックレビュー&メタ解析

    坪内愛佑, 松本ゆうり, 三原貴之, 岡本侑子, 池上眞太郎, 高橋実秀, 中林花音, 西本直人, 水上雄貴, 村石琢真, 五十嵐裕貴, 榎木裕紀, 田口和明, 松元一明

    [Domestic presentation]  第9回日本老年薬学会学術大会, 

    2025.06

  • 単剤接種又は併用接種による肺炎球菌ワクチンの有効性と安全性比較: システマティックレビュー&メタ解析

    岡本侑子, 松本ゆうり, 三原貴之, 坪内愛佑, 池上眞太郎, 高橋実秀, 中林花音, 西本直人, 水上雄貴, 村石琢真, 五十嵐裕貴, 榎木裕紀, 田口和明, 松元一明

    [Domestic presentation]  第9回日本老年薬学会学術大会, 

    2025.06
    , 

    Poster presentation

  • 肺MAC標準治療薬3剤含有リポソームの調製

    宇山杏奈, 田口和明, 岡本侑子, 榎木裕紀, 松元一明

    [Domestic presentation]  日本薬学会第145年会, 

    2025.03

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本医療薬学会, 

    2025.05
    -
    Present

  • 日本口腔ケア学会, 

    2025.03
    -
    Present

  • 日本老年薬学会, 

    2025.03
    -
    Present
Page Top ▲